|
Update on Therapeutic Advances in T-Cell Lymphoma: Live Webinar
T-cell lymphoma is a rare but deadly hematologic malignancy that is difficult to diagnose and has limited treatment options. Join us for this 2021 update to gain expert perspectives on:
- Differential diagnosis
- Clinical studies supporting the efficacy and safety of novel agents
- Emerging combination and sequential treatment strategies
In addition, our expert faculty provide evidence-based advice regarding:
- Tailoring treatment plans to individual patients
- Managing treatment-rel... |
|
|
Understanding Evolving Therapeutic Strategies for Graft-Versus-Host Disease (Module 1: Diagnosis, Risk Assessment, and Staging; Module 2: Current and Emerging Therapeutic Strategies)
STATEMENT OF NEED
Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplant (HSCT), affecting between 40% and 60% of patients and accounting for 15% of posttransplant mortality. Acute GVHD is the second-leading cause of transplant-related mortality and typically targets the skin, gastrointestinal tract, and liver. Chronic GVHD often presents during the first year following HSCT but may develop in subsequent years and most commonly affects the ... |
|
Optimal Prehospital Management of Seizure Emergencies
In this program, the faculty will review and provide updates on the guidelines for managing seizure emergencies and address how participants can reduce the barriers to prehospital treatment through the use of Seizure Action Plans. They also will discuss recent clinical trials that may improve caregiver acceptance of rescue medications for status epilepticus. In addition, the faculty will address the similarities and differences in managing seizure emergencies for pediatric and adult patients. |
|
Research Updates in Gout: Improving Response Rate to Therapy
Dr. Brian Mandell and Dr. Naomi Schlesinger discuss recent published evidence related to gout, as well as study results presented at the American College of Rheumatology Convergence 2020 virtual annual meeting. Dr. Schlesinger begins with an introduction on a recent published systematic review indicating that the manifestations of gout extend beyond the joints, affecting other organs and tissues. Dr. Schlesinger also provides an overview of some of the challenges encountered in clinical practi... |
|
A Case-Based Roadmap for Improved Patient Outcomes in Psoriatic Arthritis
Patients with psoriatic arthritis (PsA) experience significant disease burden due to incomplete diagnostic evaluation and suboptimal use of effective therapies. In this case-based activity, Dr. Leonard Calabrese of the Cleveland Clinic addressing these practice gaps by sharing his recommendations for patient management at critical decision points in the diagnosis and treatment of patients with PsA. Dr. Calabrese also discusses the important role of shared decision-making over the course of the... |
|
Immunotherapy Advances in RRMM: An Educational Journey
Multiple myeloma has become the most common hematologic malignancy in the United States adult population with over 120,000 people living with the disease. Despite new and more effective treatments, multiple myeloma, unfortunately, remains largely incurable with relapse and disease progression still common.
Dr. Ola Landgren Chief of the Myeloma Service at Memorial Sloan-Kettering Cancer Center and professor of medicine at Cornell Medical College discusses advances in the field of immunothera... |
|
Meeting the Medical Needs of Patients with Ulcerative Colitis During the COVID-19 Pandemic
The COVID-19 pandemic is an unprecedented challenge for all healthcare systems worldwide. Gastroenterologists and clinicians who actively manage patients with inflammatory bowel disease (IBD), including ulcerative colitis (UC), need to ensure they are taking steps to minimize the risk of infection for their patients.
Russell D. Cohen, MD, shares his expert perspective as an author of the recently published AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the C... |
|
Eosinophilia in Patients With Asthma: A Sign of Eosinophilic Granulomatosis With Polyangiitis (EGPA)
PART 1: Welcome to this overview of eosinophilic granulomatosis with polyangiitis with Michael Wechsler, MD. In this activity, Dr. Wechsler reviews the pathogenesis, diagnosis, prognosis, and treatment of EGPA. This presentation will help you recognize EGPA and differentiate it from other diagnoses and other small-vessel vasculitides, and develop treatment plans based on the patient’s prognosis and response to first-line treatments.
PART 2: Welcome to this video question and answer inte... |
|
|
Update on Immunotherapeutic Strategies for Advanced Merkel Cell Carcinoma
STATEMENT OF NEED
Merkel cell carcinoma is a rare and aggressive neuroendocrine tumor of unknown origin that typically presents in older white and immunocompromised adults. An estimated 2,488 cases are diagnosed in the United States annually (Paulson et al, 2018). The incidence of MCC has risen rapidly during the past few decades, which has been attributed in part to people living longer with increased sun exposure and weakened immune systems, a feature that suggests an infectious origin an... |
|
|
New Data and Clinical Perspectives on the Treatment of Metastatic Hormone-Sensitive Prostate Cancer
STATEMENT OF NEED
Prostate cancer is the most common tumor type affecting men in the United States. An estimated 191,930 new cases are diagnosed annually, and 33,330 people die from the disease (ACS, 2020). Most patients with metastatic hormone-sensitive prostate cancer (HSPC) present with relapse after local treatment, while approximately 5% of all prostate cancer patients present with de novo metastatic HSPC (Ng et al, 2020). The five-year overall survival rate for metastatic HSPC remains... |
|
|
Expert Guidance on New Advances in Renal Cell Carcinoma
STATEMENT OF NEED
Kidney cancer accounts for approximately 4% of all cancer diagnoses in the United States (ACS, 2020). An estimated 73,750 new cases are reported annually and 14,830 people die of the disease. Renal cell carcinoma, which comprises nearly 90% of all kidney cancers, is characterized by a lack of early warning signs, diverse clinical manifestations, and resistance to radiation and chemotherapy. Due to its often asymptomatic presentation, many patients have advanced disease at ... |
|
|
Virtual Tumor Board: Optimizing Personalized Care Plans for Patients With Metastatic Breast Cancer
STATEMENT OF NEED
Breast cancer accounts for approximately 30% of cancer diagnoses among women in the United States and is the second-leading cause of cancer death in this population (ACS, 2020). Although many women benefit from regular screening as well as earlier and improved treatment, approximately 6% present with metastatic disease, and up to 30% with no initial lymph node involvement eventually develop metastatic disease (Siegel et al, 2020; Mortensen et al, 2018). Women with metastat... |
|
|
Virtual Tumor Board: Optimizing Personalized Care Plans for Patients With Relapsed/Refractory Follicular Lymphoma
STATEMENT OF NEED
Of the estimated 74,200 new cases of non-Hodgkin lymphoma each year in the United States, approximately 22% are FL, an indolent, difficult-to-treat B-cell malignancy (ACS, 2019; NCCN, 2019). Most patients are diagnosed at an average age of 63 years (NCI, 2019). Despite the introduction of novel therapies during the past decade, complications such as delayed presentation and treatment and evolving disease subtypes continue to hamper patient outcomes, and multiple recurrence... |
|
|
Virtual Tumor Board: Optimizing Personalized Care Plans for Patients With Advanced Soft Tissue Sarcoma
STATEMENT OF NEED
Soft tissue sarcomas are a heterogeneous group of malignancies that arise primarily from the mesodermal tissues of the extremities, trunk and retroperitoneum, and head and neck. An estimated 13,130 new cases are diagnosed in the United States annually and 5,350 people die of the disease. Surgical resection is the mainstay of treatment for localized soft tissue sarcoma, with radiation and chemotherapy commonly used as adjuncts. However, nearly 50% of patients will experienc... |
|
|
Navigating the Recent Rheumatoid Arthritis Guidelines to Achieve Disease Remission and Reduce Patient
Roy M. Fleischmann, MD, discusses the latest evidence for the management of patients with moderate-to-severe rheumatoid arthritis who do not achieve treatment goals with initial disease-modifying anti-rheumatic drug therapy. A key treatment principle emphasized by Dr. Fleischmann is using a treat-to-target approach guided by validated tools for assessing disease activity and patient-reported outcomes. Among the treatment options, Dr. Fleischmann highlights the pharmacology of the latest approv... |
|
Navigating Advancements in Diagnosis & Treatment of Axial Spondyloarthritis
More than 80% of the population has significant back pain at some point in their life, with 30% of adults in the United States stating they have chronic low back pain at any given time; 5% of whom have inflammatory back pain. Axial spondyloarthritis (axSpA) affects almost 1.5% of patients with inflammatory back pain; however, the majority of individuals suffering with back pain are not being treated by a rheumatologist, which only exacerbates the challenge to diagnose those with axSpA.
Dr.... |
|
Research Developments in Atopic Dermatitis
Welcome to this activity focusing on new research related to atopic dermatitis presented as posters at the 2020 virtual annual meetings of the American Academy of Dermatology and the American Academy of Allergy, Asthma, and Immunology. The posters focus on new data related to the use of advanced therapies for atopic dermatitis. Beyond discussing the methods and results of each poster, the faculty, Drs. Steven Feldman and Alan Fleischer, Jr., share their views on the implication of the trial re... |
|
|
Defining Personalized Care Plans in Metastatic Colorectal Cancer
STATEMENT OF NEED
Colorectal cancer (CRC) is the third leading cause of cancer death among men and women in the United States. An estimated 145,600 new cases are diagnosed annually and 51,020 people die of the disease. When detected and treated early at a localized stage, the 5-year survival rate is 90%. However, because CRC initially exhibits no symptoms and the use of routine screening is suboptimal, most patients are diagnosed at later stages. Approximately 21% of patients present with m... |
|
Right Patient, Right Treatment, Right Time: Utilizing Early, High-Efficacy Therapies to Improve Outcomes in RRMS
Recent studies have demonstrated the benefits of early and aggressive treatment strategies in reducing disability progression and the frequency of relapses in patients with relapsing remitting multiple sclerosis (RRMS), marking a paradigm shift in the treatment of patients with RRMS. The traditional escalation approach is now often set aside in favor of the more individualized "induction" approach, which utilizes "early and aggressive" treatment with high-efficacy disease-modifying therapies (... |
|
|
Beyond the Old Paradigms: Novel Approaches to the Treatment of Chronic Idiopathic Constipation
Chronic idiopathic constipation (CIC) affects 35 million adults in the United States, making it one of the most common gastrointestinal disorders. Despite the high prevalence, CIC is often underdiagnosed and undertreated, which exacts a functional, psychosocial, and economic toll on patients and their loved ones. The current treatment goal in CIC is multi-symptom relief, but only 16% of patients with CIC are on prescription therapy, and they often only obtain partial relief, with many using la... |
|
|
Giving Shingles Immunization Your Best Shot: Implementing a Shingles Vaccination Protocol in Your Practice
Shingles, or herpes zoster, is a common secondary infection for older patients. Almost all individuals over the age of 50 are latently infected with varicella zoster virus (VZV) and therefore are at risk of developing shingles with reactivation of latent VZV. Individuals who develop shingles often experience debilitating postherpetic neuralgia (PHN), secondary skin infections, eye problems, or neurologic conditions including an increased risk of stroke.
Despite the existence of vaccines, th... |
|
|
Retooling for Modern Management of Progressive MS: An Interactive, Case-Based Activity
The approval of ocrelizumab for primary progressive multiple sclerosis (PPMS) was groundbreaking, and more recently the MS community bore witness to another major breakthrough in MS management when siponimod was approved for secondary progressive MS (SPMS). Additionally, new investigational agents such as MD1003 (high-dose biotin) and masitinib are also being evaluated for treatment of PPMS, and clinical data for both show promise for patients with SPMS.
However, despite these advances, stu... |
|
|
Looking Ahead: Integrating Emerging Therapies and Tools in Early-Stage Alzheimer's Disease
Alzheimer's disease (AD), a heterogeneous, neurodegenerative condition with an insidious onset and slow progression, is the leading cause of disability and morbidity as well as the sixth-leading cause of death in the United States. Diagnosing AD is often complicated due to its varied clinical symptomatology and unknown etiology, and currently only symptomatic therapies are available.
Recent clinical trials investigating disease-modifying therapies (DMTs) that could slow or reverse the progr... |
|
|
Hitting the Target with IL-23 Inhibitors in Psoriatic Arthiritis
Psoriatic arthritis (PsA) is a chronic, inflammatory, musculoskeletal disease with a significant impact on quality of life and functional ability. Despite the data showing the overall impact of PsA, delays in diagnosis are common, which can lead to long-term joint damage and functional disability.
In this CME Outfitters Live and OnDemand activity, expert faculty will focus on assessment, treatment, and management strategies to provide patients with the best treatment aligned with evolving e... |
|
|
Keeping the Beat: Screening and Management of High-Risk Patients with Non-Valvular Atrial Fibrillation
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, projected to affect 12 million Americans by 2030. However, a significant number of AF cases, particularly non-valvular atrial fibrillation (NVAF) remain undiagnosed, putting patients at risk for severe cardiovascular (CV) complications, including increased risk of stroke. It is imperative that clinicians identify the symptomatology of AF and effectively diagnose NVAF, as these complications can potentially be avoided by ... |
|
|
Targeted Therapy for HER2 and HER3-Positive Breast Cancer: Navigating the Evolving Treatment Landscape
Statement of Need
Breast cancer (BC) is a heterogeneous disease with human epidermal growth factor receptor 2 (HER2) overexpression and/or amplification observed in 20%-30% of cases. HER2-positive (+) BC correlates with poor clinical outcomes unless appropriately treated with targeted therapy. Despite significant therapeutic advances, many patients experience disease progression with resistance to targeted agents developing over the course of treatment.
This CME Outfitters Live and OnDe... |
|
Tumor-induced Osteomalacia (TIO): Diagnosis and Management
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic condition commonly characterized by bone pain, muscle weakness and fractures. These tumors secrete excess fibroblast growth factor 23 (FGF23) which inhibits the sodium phosphate renal co-transporters and suppresses 1α hydroxylase activity, thereby decreasing renal reabsorption and increased urinary phosphate excretion. As a result, unexplainable hypophosphatemia with a variety of musculoskeletal abnormalities are the most common sympto... |
|
|
Neuroendocrine Tumors (NETs) Research Highlights from ENDO 2020
Although the 2020 Endocrine Society’s annual meeting (ENDO 2020) did not take place as scheduled, abstracts, including new information and data on neuroendocrine tumors (NETs) were published. This CME activity highlights the latest information about NETs from ENDO 2020 and provides expert analysis of its clinical relevance for busy members of the care team in order to help them care for patients with these rare diseases. |
|
|
Exploring Novel Treatment Strategies for Metastatic Colorectal Cancer
STATEMENT OF NEED
Colorectal cancer (CRC) is the third leading cause of cancer death among men and women in the United States. An estimated 145,600 new cases are diagnosed annually and 51,020 people die of the disease. When detected and treated early at a localized stage, the 5-year survival rate is 90%. However, because CRC initially exhibits no symptoms and the use of routine screening is suboptimal, most patients are diagnosed at later stages. Approximately 21% of patients present with m... |
|
|
Clinical Updates and Expert Guidance in Prostate Cancer
STATEMENT OF NEED
Prostate cancer is the most common tumor type affecting men in the United States, with an estimated 174,650 new cases reported each year. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to antiandrogens frequently develops over time. The transition from castration-sensitive to castration-resistant disease has yet to be understood and represents a significa... |
|
|
Virtual Tumor Board: Diagnosis and Management of Myelodysplastic Syndromes
STATEMENT OF NEED
Myelodysplastic syndromes (MDS) are a group of heterogeneous hematopoietic disorders derived from an abnormal multipotent progenitor cell, characterized by ineffective hematopoiesis, bone marrow failure, and peripheral blood cytopenias. Survival in MDS ranges from a median of 5.3 years in lower-risk patients to as little as 0.8 years in higher-risk patients. Mortality is usually a result of infection, hemorrhage, and/or iron overload secondary to red blood cell transfusion... |
|
|
Mucopolysaccharidoses (MPSs) Highlights from WORLDSymposium 2020
At WORLDSymposium 2020, new information and data were presented on Mucopolysaccharidoses (MPSs), a group of genetic lysosomal disorders. This CME activity highlights the latest information about MPSs from WORLDSymposium and provides expert analysis of its clinical relevance for busy members of the care team in order to help them care for patients with these rare diseases. |
|
|
Gaucher Disease Highlights from WORLDSymposium 2020
At WORLDSymposium 2020, new information and data were presented on Gaucher disease, a rare lysosomal storage disorder. This CME/CNE activity highlights the latest information about Gaucher disease from WORLDSymposium and provides expert analysis of its clinical relevance for busy members of the care team in order to help them care for patients with this rare disease. |
|
|
Fabry Disease Highlights from WORLDSymposium 2020
At WORLDSymposium 2020, new information and data were presented on Fabry disease, a rare lysosomal storage disorder. This CME/CNE activity highlights the latest information about Fabry disease from WORLDSymposium and provides expert analysis of its clinical relevance for busy members of the care team in order to help them care for patients with this rare disease. |
|
|
@MondayNightIBD OnDemand: Addressing the Cases That Challenge Your Practice
Statement of Need
Gastroenterologists are trailblazers in health care social media, and #MondayNightIBD (#MNIBD) has harnessed that energy to establish gastroenterologists as not just social media influencers but as clinical practice influencers as well. #MNIBD is not just a weekly social media conversation - it is an international platform that is moving the field forward by crowdsourcing the expertise of leading inflammatory bowel disease (IBD) experts, community clinicians, and patients ... |
|
|
Navigating the New Psoriasis Guidelines: Implications for Clinical Practice
Statement of Need:
The American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) have recently released new joint guidelines that outline best practices for the management of psoriasis (PsO) with biologics, the need for awareness and attention to comorbidities, and guidelines for pediatric PsO treatment. Clinicians must ensure that they are aware of these guidelines and of strategies to incorporate them into clinical practice, including the integration of biologic ther... |
|
|
At-Risk Patients Hidden in Plain Sight: Real-World Strategies for Screening and Treating Hepatitis B Virus
Statement of Need
Chronic hepatitis B virus (HBV) remains a global epidemic, resulting in significant morbidity and mortality. In 2015, there were 257 million people worldwide infected with HBV. In 2016, only 10.5% were diagnosed, with only 16.7% receiving treatment, and without intervention, there are 19 million deaths anticipated by the end of 2020. These numbers are startling as they exist despite the availability of effective treatment, and this is in part due to lack of clinician knowl... |
|
|
A Deeper Dive into NASH Diagnosis and Treatment: An Augmented Reality Experience
Statement of Need
Obesity and diabetes are on the rise, leading to an increased prevalence of non-alcoholic fatty liver disease (NAFLD), which in some cases may progress to non-alcoholic steatohepatitis (NASH). NAFLD effects approximately 30% of the U.S. population, with NASH effecting about 5%. NASH comes with a significant risk of progression to advanced liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Disease models project that the number of individuals with end-stage live... |
|
|
Food Allergy: From Primary Prevention to Treatment and Intervention Online
This online offering includes 19 videos of lectures and panel discussions on the diagnosis and management, specific syndromes, treatment, and research and prevention of food allergy. The videos were recorded at a live course that took place at a live AAAAI course held in early September, 2019.
The intent of the videos is to allow learners to increase their knowledge related to the diagnosis and management of food allergic patients. It highlights the latest evidence related to food allergie... |
|
|
Conversations from the World of Allergy: Podcast Episodes for Credit
This podcast features interviews on a wide variety of allergy/immunology topics. It is our hope that the conversations provide evidence-based information that is useful to clinicians, researchers and patients, alike.
Some episodes are available for CME credit. All podcast episodes are available at https://www.aaaai.org/professional-education-and-training/podcasts |
|
|
Virtual Patient: Asthma in the Older Adult
This patient simulation requires an evaluation and creation of a treatment plan for an older adult (>65 years old) with asthma. The case involves identification of differences and similarities between asthma and COPD in older adults and consideration of medications and co-morbid conditions that may complicate the management of asthma in this population. A summary of the literature supporting best practices in asthma care in the older adult will be provided. |
|
|
Pharmacologic Treatment of ADPKD: Monitoring and Risk Mitigation
The advent of pharmacologic therapy for ADPKD offers new opportunities to delay the progression of renal decline for patients. However, health care providers need to know how to identify patients at high risk of progression when considering therapy and how to manage patients receiving disease-modifying therapy.
This is the third of three related activities on the pharmacologic management of patients with ADPKD. The activities follow a patient with ADPKD through her journey from diagnosis t... |
|
|
Pharmacologic Treatment of ADPKD: Successful Initiation of Pharmacologic Therapy for ADPKD
The advent of pharmacologic therapy for ADPKD offers new opportunities to delay the progression of renal decline for patients. However, health care providers need to know how to identify patients at high risk of progression when considering therapy and how to manage patients receiving disease-modifying therapy.
This is the second of three related activities on the pharmacologic management of patients with ADPKD. The activities follow a patient with ADPKD through her journey from diagnosis ... |
|
|
Pharmacologic Treatment of ADPKD: Patient Selection and Individualization
The advent of pharmacologic therapy for ADPKD offers new opportunities to delay the progression of renal decline for patients. However, health care providers need to know how to identify patients at high risk of progression when considering therapy and how to manage patients receiving disease-modifying therapy.
This is the first of three related activities on the pharmacologic management of patients with ADPKD. The activities follow a patient with ADPKD through her journey from diagnosis t... |
|
|
Clinical Case Challenges: Evidence-Based Strategies in the Diagnosis and Management of Bipolar Depression
Primary care is frequently the first point of contact for individuals with bipolar depression. Although bipolar depression is often diagnosed and managed by psychiatrists, access to psychiatrists can be a limiting factor to care delivery. In one study, fewer than half of patients referred from primary care scheduled an appointment with a psychiatrist, and fewer than half of scheduled visits were attended.
Many patients with bipolar depression are successfully managed in the primary care set... |
|
|
New Horizons in Pustular Psoriasis: Will You Be Ready?
Pustular psoriasis may be rare, but it is associated with high rates of morbidity, mortality, and recurrence, and it can be difficult to treat.
Clinicians, it’s time to get ready to translate the rapidly evolving guidance and emerging science to improve outcomes for our pustular psoriasis patients. Join your colleagues, and expert faculty Dr. Mark Lebwohl in these upcoming virtual, small-group, CME Meet Ups to discuss:
- Lack of U.S guidance that complicates diagnosis and disease
- Re... |
|
|
8-Night Holland & Belgium Tulip Time CME AWAY® River Cruise
DINING
- All meals onboard, prepared using the finest and freshest ingredients
- Captain’s Welcome and Farewell Receptions
- Welcome and Farewell Gala Dinners
- Unlimited beverages onboard, including fine wine, beer, spirits, specialty coffee and tea, soft drinks and mineral water
EXCURSIONS
- 6 days of excursions, including “Choice Is Yours” options, all fully hosted by English-speaking Local experts
- Guided “Do as the Locals Do,” “Village Day,” “Go Active” and “Ge... |
|
|
9-Night Kenya CME AWAY® Land Tour - Neurology and Orthopedics: Brain vs Brawn
The concept of the safari was born in Kenya where in Kiswahili the word
safari means "journey”. East Africa has the reputation as the quintessential safari destination for good reason. The region’s dramatic contrasts and endless array of ecosystems showcases a variety of wildlife, making this one of the top destinations for African safari vacationers. |
|
|
7-Night Jamaica CME AWAY® Resort - Dermatology & Aesthetic Medicine: Recent Advancements & Exciting Developments
The all-new Sandals South Coast is the perfect combination of European civility in anall-beachfront resort. From all-new Over-the-Water Bungalows, an overwater bar, and a romantic Over-the-Water Chapel, Sandals South Coast brings guests closer than ever to the water. Set on a 2-mile stretch of Jamaica's south coast's most pristine white-sand beach and nestled within a 500-acre nature preserve, this spectacular seaside oasis features three distinctive European Villages. Relax by one of three po... |
|
|
13-Night Dubai, Abu Dhabi & Muscat CME AWAY® Land Tour - Emergency Medicine: Practical Advice and Contemporary Driven Evidence for Common Presentations
Dubai is a stirring alchemy of profound traditions and ambitious futuristic vision wrapped into starkly evocative desert splendour. Proudly modern and cosmopolitan, Abu Dhabi is the UAE's forward-thinking cultural heart where nothing stands still – except perhaps the herons in its mangroves. Scenically wedged between mountains and ocean, with old forts and excellent museums, an opera house and flower-filled parks, the gentle city of Muscat is a delight to visit. Its name means ‘safe anchor... |
|